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The novel structural proteins (NSPs) are encoded 
by a family of related but distinct cDNAs expressed 
from a single gene [1]. This gene corresponds to locus 
HCMOGT-1 on chromosome 17p11.2 and encodes 
NSP5a3a and three other splice variants. NSP5a3a is 
highly expressed in some tumor cell lines and in the 
testis but not in other normal body tissues [1]. Further 
studies revealed that NSP5a3a interacts with the nucleolar 
phosphoprotein B23, which plays multiple roles in cell 
growth and proliferation [2] and with hnRNP-L [3]. 
In this issue of Oncotarget, D’Agostino and Giordano 
investigate the effect of over-expressing NSP5a3a in 
head and neck squamous cell carcinoma (HNSCC) cell 
lines [4]. HNSCC is one of the 10 most common cancers 
worldwide and the overall survival rate for HNSCC is 
still low even with the latest innovations in both basic and 
clinical research [5]. Thus, there is an urgent requirement 
to identify novel targets for HNSCC. The present study 
indicates that NSP5a3a may represent such a potential 
target. When NSP5a3a was over-expressed in HN30 
HNSCC cells, there was a robust induction of apoptosis. 
The authors went on to investigate the molecular 
mechanisms involved in the effects of NSP5a3a in HN30 
and FADU HNSCC cells and found no changes in p53, 
B23, Bax or caspase 3 but a possible involvement of p73. 
These data raise some interesting questions: “could 
NSP5a3a be a target for the therapy of HNSCC?” and 
“could agonists of NSP5a3a be developed and used in 
combination with chemotherapy and/or radiotherapy for 
HNSCC?”. The development of such therapies likely 
requires a more detailed elucidation of the mechanism 
of action of NSP5a3a involving characterizing NSP5a3a 
biochemically and the development of inhibitors/
agonists for the signal transduction pathways involved. In 
conclusion, these data are an interesting starting point to 
investigate the role of this protein in cancer in general and 
HNSCC in particular.
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